| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1507 | 2020 |
| Reduced mutation rate in exons due to differential mismatch repair J Frigola, R Sabarinathan, L Mularoni, F Muiños, A Gonzalez-Perez, ... Nature genetics 49 (12), 1684-1692, 2017 | 150 | 2017 |
| Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer J Frigola, A Navarro, C Carbonell, A Callejo, P Iranzo, S Cedrés, ... Molecular oncology 15 (4), 887-900, 2021 | 30 | 2021 |
| Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer P Iranzo, A Callejo, JD Assaf, G Molina, DE Lopez, D Garcia-Illescas, ... Frontiers in medicine 9, 875974, 2022 | 28 | 2022 |
| Variable interplay of UV-induced DNA damage and repair at transcription factor binding sites J Frigola, R Sabarinathan, A Gonzalez-Perez, N Lopez-Bigas Nucleic acids research 49 (2), 891-901, 2021 | 27 | 2021 |
| Interrelations between patients’ clinicopathological characteristics and their association with response to immunotherapy in a real-world cohort of NSCLC patients A Callejo, J Frigola, P Iranzo, C Carbonell, N Diaz, D Marmolejo, JD Assaf, ... Cancers 13 (13), 3249, 2021 | 10 | 2021 |
| Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort S Cedres, JD Assaf, P Iranzo, A Callejo, N Pardo, A Navarro, ... Scientific Reports 11 (1), 21357, 2021 | 8 | 2021 |
| DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity K Valencia, M Echepare, Á Teijeira, A Pasquier, C Bértolo, C Sainz, ... Journal of Experimental Medicine 219 (12), e20220726, 2022 | 6 | 2022 |
| High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC J Frigola, C Carbonell, P Iranzo, N Pardo, A Callejo, S Cedres, ... Journal for immunotherapy of cancer 10 (4), 2022 | 5 | 2022 |
| Altered oncomodules underlie chromatin regulatory factors driver mutations J Frigola, A Iturbide, N Lopez-Bigas, S Peiro, A Gonzalez-Perez Oncotarget 7 (21), 30748, 2016 | 4 | 2016 |
| Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation Q Serra-Camprubí, H Verdaguer, W Oliveros, N Lupión-Garcia, ... Clinical Cancer Research 29 (2), 432-445, 2023 | 3 | 2023 |
| Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC C Carbonell, J Frigola, N Pardo, A Callejo, P Iranzo, A Valdivia, I Priano, ... Molecular oncology 17 (5), 779-791, 2023 | 1 | 2023 |
| Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1). P Iranzo, A Callejo, A Pedrola, N Pardo Aranda, A Navarro, ... Journal of Clinical Oncology 38 (15_suppl), e15137-e15137, 2020 | 1 | 2020 |
Ramon AmatResearcher @VHIOVerified email at vhio.net
